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Primary Prevention of Bleeding from 
Oesophageal Varices
Christos Triantos1, Jiannis Vlachogiannakos2
A B S T R A C T
Variceal bleeding is the most serious complication of patients with cirrhosis and 
portal hypertension. Mortality related to variceal bleeding has been falling in recent 
years but is still considered among the leading causes of death in these patients. 
Therefore, the issue of primary prophylaxis of variceal bleeding is an important one. 
In the pre-primary prophylaxis setting (prevention of formation/growth of varices) all 
cirrhotics should be screened for varices at diagnosis although there is no currently 
indication for treating patients in order to prevent the formation of varices. Areas 
requiring further study include the natural history of low-risk varices and treatment 
possibilities for the decrease or the prevention of the development and/or the progres-
sion of varices. Patients with small varices could be treated with beta-blockers, which 
have been proved effective in reducing the risk of first variceal bleeding in patients 
with medium and large oesophageal varices. Endoscopic band ligation seems to be 
more effective in recent trials, but concerns have been raised regarding its safety. 
Further, studies are required to clarify whether the use of the combination of band 
ligation and beta-blockers is better than each treatment alone. The future aim is to 
improve current medical therapy taking into consideration the cost-effectiveness and 
the quality of life.
I N T R O D U C T I O N
Liver cirrhosis is responsible for 90% of patients with portal hypertension in Eu-
rope and North America. Portal hypertension represents the most serious complica-
tion of cirrhosis and results in the development of portosystemic shunts comprising 
esophageal varices [1].
It is considered that one third of cirrhotic patients with esophageal varices will 
experience the first episode of variceal haemorrhage within one year following the 
diagnosis of varices. The risk for the first episode of variceal bleeding is higher in 
patients with severe liver failure, large varices and red spots found endoscopically. 
Moreover, bleeding-related mortality is extremely high as 30-50% of patients will die 
within six weeks from the first episode of bleeding [1].
The bad prognosis of variceal bleeding has led to attempts both, to identify pa-
tients in high-risk for bleeding and to prevent it. Many different therapies have been 
assessed over the last 30 years including surgery, administration of drugs (non selective 
beta-blockers, isosorbide mononitrate or the combination of them) and endoscopic 
eradication of varices (sclerotherapy or banding ligation).
REVIEW
1Hepatobiliary and Transplantation 
Unit, Royal Free Hospital, London, UK
22nd Department of Gastroenterology 
“Evangelismos” Hospital, Athens, 
Greece
HOSPITAL CHRONICLES 2006, 1(2): 83–92
Address for Correspondence:
Jiannis Vlachogiannakos M.D.
2nd Department of Gastroenterology 





KEY WORDS: esophageal varices, primary 
prevention, beta-blockers, nitrates, 





HOSPITAL CHRONICLES 1(2), 2006 PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING
85
N A T U R A L  H I S T O R Y  O F  V A R I C E S
When cirrhosis is diagnosed, varices are present in 30% of 
patients with well compensated cirrhosis and 60% of patients 
with decompensated cirrhosis [2]. After varices are formed 
their size increases and occasionally they bleed. It has been 
reported that they increase by 10-20% in the first two years 
after the first endoscopic observation [1]. 
In a study by Pagliaro et al, 4% of cirrhotic patients without 
varices at the first endoscopy, and 25% of patients with small 
varices developed large varices after a 6 year follow-up. How-
ever, in another study by Cales et al, large varices were found 
in 31% of patients without varices and in 70% of patients with 
first degree varices at initial endoscopic examination, after 
a 2 year follow-up. These differences have been attributed 
to different definitions of the size of varices as well as to the 
large percentage of active alcoholic abusers included in the 
French study [3].
P R E D I C T I O N  O F  T H E  P R E S E N C E  
A N D  D E V E L O P M E N T  O F  E S O P H A G E A L  
V A R I C E S
Many efforts have been made to find clinical parameters 
that could accurately predict the presence of varices as endos-
copy is an invasive procedure and is unnecessary for well-com-
pensated cirrhotics with little probability of having developed 
varices [4]. A French group has suggested that platelet count 
and prothrombin index have a diagnostic accuracy of 72% in 
the prediction of the presence of varices, although their pre-
dictive power was suboptimal for clinical use and would not 
obviate the necessity for screening endoscopy [5]. In another 
study that enrolled 143 patients with Child Pugh A/B liver cir-
rhosis - mainly of viral aetiology - the presence of varices was 
correlated to PT index <70%, platelets <100000/mm3 and 
ultrasound-determined portal vein diameter >13mm [6].
It is widely accepted that esophageal varices are not 
formed if portal pressure, indirectly assessed with HVPG 
(hepatic venous pressure gradient) does not exceed 10 -12 
mmHg. Thus, screening for the development of varices could 
be replaced by HVPG [7]; however not all patients of this 
group have varices at endoscopic examination.
F O L L O W - U P  O F  P A T I E N T S  W I T H  
E S O P H A G E A L  V A R I C E S
There is no consensus on the optimal intervals for sur-
veillance endoscopy. In an AASLD symposium in 1996 [8], 
it was suggested that in Child-Pugh A patients endoscopic 
evaluation should be performed when there are indications 
of portal hypertension (platelets < 140.000, portal vein diam-
eter >13 mm, and ultrasound indication of collateral blood 
flow). In Child-Pugh B and C patients endoscopic examina-
tion should be performed at the time of diagnosis. Patients 
without varices should undergo endoscopic examination every 
2 years if liver function is stable, or once a year if there are 
signs of deterioration. As the large varices development rate 
is higher in patients with small varices at initial endoscopic 
evaluation than in patients without varices, patients with small 
varices should undergo endoscopic examination annually. In a 
recent consensus workshop that was held in Baveno [9], it was 
proposed that all patients with liver cirrhosis should undergo 
endoscopic examination at the time of initial diagnosis (See 
Baveno IV recommendations in Table I). 
TABLE 1. Recommendations of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal 
hypertension.
• all cirrhotics should be screened for varices at diagnosis
• there is no indication for treating patients in order to prevent the formation of varices
• patients with small varices could be treated with non-selective beta-blockers to prevent progression of varices and bleeding, but further 
studies are needed before formal recommendation on their use can be made
• patients with small varices with red wale signs or of Child-Pugh C class have an increased risk of bleeding and may benefit from 
treatment
• non selective beta-blockers reduce the risk of first variceal bleeding in patients with medium and large oesophageal varices
• ISMN alone must not be used
• There are not enough data to support the use of the combination of beta-blockers plus ISMN or spironolactone plus beta-blockers 
• EBL is useful in preventing variceal bleeding in patients with medium and large varices
• EBL is more effective than non-selective beta-blockers in preventing first variceal bleeding but does not improve survival. However, the 
long term benefits of EBL are uncertain because of the short duration of follow up
• EBL should be offered to patients with medium/large varices and contraindications or intolerance to beta-blockers.
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R I S K  O F  F I R S T  V A R I C E A L  B L E E D I N G
It has been postulated that the risk factors of esophageal 
varices rupture are the advanced liver failure, as assessed with 
Child - Pugh score, large varices and the presence of red spots 
at endoscopy. However, the above risk factors were found in 
only 1/3 of patients with variceal haemorrhage. Therefore, 
other factors should probably be taken into consideration in 
the evaluation of variceal haemorrhage risk.
Recently, the interest of hepatologists has been focused 
on the role of hemodynamic factors in the development and 
rupture of varices. Some studies have shown that HVPG con-
stitutes an independent risk factor of bleeding and death [10]. 
Variceal bleeding does not occur if HVPG does not exceed 
the limit of 12 mmHg. Beyond this limit there is no linear 
correlation between the likelihood of bleeding and HVPG, 
although pressure is usually high in patients who bleed. In a 
recent study, cirrhotic patients under pharmacologic therapy 
were followed-up for a long period reaching 8 years. It was con-
firmed that the risk of variceal bleeding is negligible if HVPG 
decreases by ≥20% or has a value of ≤12 mmHg [11].
It has been suggested that variceal pressure also represents 
an independent risk factor for the first bleeding episode [12] 
and an important prognostic factor in patients with portal 
hypertension of cirrhotic or non-cirrhotic aetiology [13]. It 
has also been reported that it constitutes a more reliable 
prognostic indicator of variceal rupture compared to HVPG 
but its measurement has many technical difficulties and reli-
ability problems. It appears that the combination of clinical, 
endoscopic and hemodynamic parameters will constitute in 
the future the most reliable source of information regarding 
the risk of variceal rupture.
Other potential independent risk factors include the 
aetiology of cirrhosis, the presence of HCC, the patency of 
portal and hepatic veins, the direction of portal flow, and the 
alcohol consumption [3]. Recent studies have focused on the 
role of bacterial infection as an important factor associated 
with increased risk of rupture of esophageal varices [14].
P R E V E N T I O N  O F  G R O W T H  O F  
E S O P H A G E A L  V A R I C E S  
P H A R M A C E U T I C A L  I N T E R V E N T I O N
Beta-blockers decrease portal vein pressure in patients 
with cirrhosis and limit the development of portosystemic 
shunts in animals with portal hypertension. In a hemodynamic 
study that was published in 1997, the changes in the portal 
vein pressure following the administration of non-selective 
beta-blockers (timolol) was assessed in 50 cirrhotics with 
or without esophageal varices. Portal pressure was reduced 
significantly in all patients after timolol administration and 
reduction was higher in patients without varices supporting 
that non-selective beta-blockers are more effective if they are 
administered earlier [15].
However, in a recent study of 213 patients without esopha-
geal varices randomized to receive either timolol (108 patients) 
or placebo (105 patients), beta-blocker were not effective in 
the prevention of varices formation. It should be noted that 
the majority of patients (88%) had Child A liver failure and 
only 12% Child B. Median follow-up was 4.2 years, while mean 
daily dose of timolol was 10.8 mg [16].
Another prospective study was designed to investigate the 
efficacy of propranolol in the prevention of large esophageal 
varices development in patients with small varices or without 
varices in the oesophagus; 102 patients received propranolol 
160 mg/d and 104 patients received placebo. After a mean 
follow-up of 2 years, 31% of patients in the propranolol 
group developed large varices as compared with 14% in the 
placebo group. The authors concluded that the administration 
of propranolol is not helpful in the prevention of large varices 
development. However, it should be emphasized that one third 
of patients were lost during follow-up [17].
Finally, Mercel et al. recently found that nadolol prevents 
the progress of small size varices into medium and large 
size varices and suggested that beta-blocker prophylaxis of 
variceal bleeding in patients with compensated cirrhosis 
should be started when small esophageal varices are found 
in endoscopy [18]. 
R A N D O M I Z E D  T R I A L S  F O R  
T H E  P R I M A R Y  P R E V E N T I O N  
O F  V A R I C E A L  B L E E D I N G
S U R G E R Y  V E R S U S  N O  T R E A T M E N T
The efficacy of portocaval shunt surgery in the primary 
prevention of variceal bleeding as compared to no treatment 
has been evaluated in 4 studies [3]. The risk of bleeding 
was lower in patients who underwent surgery but the risk of 
encephalopathy was significantly increased and survival was 
significantly worse. Thus, surgery has no place in the primary 
prevention of variceal haemorrhage today and the advent of 
liver transplantation removes any rationale for prophylactic 
surgery of any kind in cirrhotics.
S C L E R O T H E R A P Y  V E R S U S  N O  T R E A T M E N T  
The efficacy of endoscopic sclerotherapy in managing 
acute variceal haemorrhage led to its application for the pre-
vention of first variceal bleeding (20 studies - 1756 patients) 
[3].
In a meta-analysis, Pagliaro L et al [3], suggested that the 
available data are insufficient to support the use of sclero-
therapy in primary prophylaxis. Furthermore, Fardy, et al in 
another meta-analysis postulated that sclerotherapy cannot 
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be recommended as routine prophylactic therapy because, 
although it appears to decrease bleeding risk significantly, it 
results in a deleterious effect in overall survival.
In a study by Strauss E et al [19] with a median follow-up 
of 2 years 21 patients were allocated to sclerotherapy and 22 
constituted the control group, 5 patients bled in the sclero-
therapy group as compared to none in the control group, while 
mortality was similar in both groups.
Recently, in a randomized study [20] that enrolled 166 
patients with II, III, and IV degree esophageal varices and 
a median follow-up of 32 months, bleeding was observed in 
25% of patients allocated to sclerotherapy and in 28% of the 
control group. There was a three-year survival rate of 62% in 
both groups. The authors conclude that sclerotherapy did not 
decrease variceal haemorrhage implications in patients with 
liver cirrhosis and low or medium bleeding risk. However, 
although bleeding related mortality decreased, overall mortal-
ity did not. Therefore, the beneficial effect of sclerotherapy, 
if any, was expected only in high risk patients.
L I G A T I O N  V E R S U S  N O  T R E A T M E N T
In recent years, endoscopic band ligation (EBL) has 
replaced sclerotherapy as the method of choice for the man-
agement of variceal bleeding. Ligation is at least as effective 
as sclerotherapy but has fewer complications [21]. Ligation of 
esophageal varices as compared to no-treatment was evaluated 
in 4 studies [22-25] that enrolled only high-risk patients.
Lay et al. found that prophylactic band ligation can reduce 
the incidence of bleeding and death after a median follow-up 
of 2 years [23]. In the study of Lo et al. although prophylactic 
band ligation did not decrease bleeding likelihood significantly 
in cirrhotic patients with large esophageal varices, it proved 
beneficial for the subgroup of Child-Pugh B patients [24]. 
Sarin et al. randomized 68 patients, to ligation (n=35) or no-
treatment (n=33). 8.6% of patients who underwent ligation 
and 39.4% who did not receive treatment experienced bleeding 
after a median follow-up of 14.1 ± 5.0 months. Furthermore, 
bleeding-related mortality was lower in the group of ligation 
as compared to that of the control group [25].
Side effects are often reported in the group of patients 
undergoing band ligation [26]. Retrosternal pain, dysphagia 
and fever have been observed roughly in 1/3 of patients. Two 
patients passed away, one because of oesophagial perforation 
related to the use of overtube [25] and one after bleeding 
related to oesophageal ulcer following ligation, which was 
complicated by aspiration [24].
Recently, in a randomized trial [27] EBL was compared 
to no treatment (NT) in cirrhotics with intolerance or con-
traindications to b-blockers for prevention of first bleeding. 
A sample size of 214 was planned with all size varices. How-
ever the trial was stopped after assessing 52 patients due to 
increased bleeding in the EBL group. Baseline severity liver 
disease and endoscopic features were similar. After a mean 
follow-up period of 19.5±13.3 months: 5 bled in EBL group 
(20%), 3 from varices (2 after banding 11 and 17 days; 1 dur-
ing procedure) and 2 from gastropathy; 2 bled in NT group 
(7,4% - 2 both varices) (p= 0.24). Deaths: 7 EBL group and 
11 NT group (p= 0.39). 60% of the bleeding in the band-
ing group was probably iatrogenic, requiring the study to be 
stopped. EBL was no better than no-treatment. This is the 
first study suggesting that EBL may be harmful when used 
as primary prophylaxis, similar to prophylactic sclerotherapy 
in the past.
N O N  S E L E C T I V E  B E T A - B L O C K E R S  V E R S U S  N O  
T R E A T M E N T
Non selective beta-blockers are more effective than selec-
tive beta-blockers, as b1 activity is important for reducing car-
diac flow and b2 activity is mandatory for reducing splanchnic 
blood flow, inducing splanchnic arterial vasoconstriction [28]; 
they also decrease blood flow in existing portosystemic shunts. 
Their favourable effect is achieved in patients with or without 
ascites and with preserved or poor liver function. They are 
also potentially effective in the prevention of bleeding from 
portal gastropathy.
There are 9 prophylactic trials [3] comprising 996 patients; 
seven of them used propranolol, and two nadolol. There was 
a statistically significant bleeding risk reduction with b-block-
ers. 205 episodes of bleeding in 507 patients were reported 
in the control groups (40.4%), and 146 bleeding episodes in 
489 patients receiving treatment (29.9%). 261 deaths in 507 
patients were recorded in the control groups (51%), and 211 
deaths in 489 patients in the groups receiving treatment (43%). 
It is estimated that 11 patients should be treated in order to 
prevent a bleeding episode. If only studies with medium, and 
large size varices are included, the effectiveness of beta-block-
ers in the prevention of bleeding is higher and 8 patients need 
to be treated in order to prevent a bleeding episode. Lastly, 
treatment with propranolol appears to be cost-effective in all 
the groups of cirrhotic patients [29].
In a meta-analysis by Poynard et al, including 589 patients 
that enrolled in 4 randomised studies with medium or large 
size varices (4 to 6 mm, or second degree or occupying more 
than 1/3 of the oesophageal lumen), 286 received beta-blockers 
(203 propranolol, and 83 nadolol) and 303 received placebo. 
Two years later, the percentage of patients who did not bleed 
was 78 ± 3% in the group who received beta-blockers and 65 
± 3% in the placebo group (p = 0.002). Two year survival 
rate was 71 ± 3% in the group that received treatment and 68 
± 3% in the control group (p = 0.34). If age and severity of 
liver failure were taken into account, survival was better in the 
group that received treatment (p = 0.09). Both, propranolol 
and nadolol were effective in preventing the first bleeding-epi-
sode. The authors concluded that beta-blockers are effective in 
preventing bleeding and decreasing bleeding related mortality. 
In another meta-analysis by Pagliaro et al, that included 9 ran-
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domised trials, there was a statistically significant reduction of 
bleeding risk (pooled odds ratio, 0.54 95% CI, 0.39 to 0.74), 
particularly in patients with medium or large size varices or in 
patients with varices and HVPG > 12 mm Hg. Nevertheless, 
although there was a tendency for mortality reduction, this 
did not reach statistical significance [3].
In a recent study by Abraczinskas et al [30], patients were 
randomized to receive propranolol that was later discontinued 
or placebo. Nine out of 49 patients (25 on propranolol, and 24 
on placebo) developed variceal haemorrhage as a complication 
(6 on propranolol and 3 on placebo). This study showed that 
if propranolol is discontinued, the likelihood of bleeding is 
similar to that of patients not receiving propranolol. Moreover, 
patients who stop beta-blockers have increased mortality as 
compared to patients who receive no treatment. Thus, it ap-
pears that propranolol should be taken for life.
In conclusion, published studies on prophylactic use of 
propranolol in patients with large varices showed a significant 
reduction of bleeding risk, but without significant increase in 
overall survival [31].
I S O S O R B I D E  M O N O N I T R A T E  ( I S M N )  V E R S U S  
N O  T R E A T M E N T
Currently, beta-blockers are the first line treatment for 
the primary prevention of variceal bleeding [32]. However, 
they cannot be administered to a significant percentage of 
patients because of contraindications or side effects (15 - 25% 
of patients) [33].
Slow-release vasodilators like dinitrate isosorbide and 
ISMN could potentially constitute an alternative solution. 
The pharmacokinetics of ISMN makes it the first choice drug 
in this category. Several studies have been recently published 
using ISMN, as it appears to decrease HVPG by causing 
systemic vasodilation, hence reducing blood entering portal 
circulation. However, systemic vasodilation also causes GFR 
reduction and renal function deterioration [34].
In a multicenter randomized double – blind study that 
enrolled 133 cirrhotics with esophageal varices and contrain-
dications or intolerance to beta-blockers (of which 67 received 
ISMN, and 66 received placebo), no difference was found in 
variceal haemorrhage risk among the two groups [33].
Therefore, it appears that available data are not sufficient 
to support monotherapy with ISMN in the primary prevention 
of variceal haemorrhage.
B E T A - B L O C K E R S  V E R S U S  I S O S O R B I D E  
M O N O N I N T R A T E  ( I S M N )
In 1993, Angelico et al. presented the results of a study 
that enrolled 118 patients and compared the efficacy of ISMN 
versus propranolol in the primary prevention of bleeding and 
suggested that ISMN is a safe and effective alternative to pro-
pranolol. Nevertheless, after 7 years of follow-up, the group of 
patients who received ISMN had higher mortality rate (only in 
patients over 50 years old) as compared to those who received 
propranolol [35].
In another study that enrolled 52 patients with ascites and 
esophageal varices, ISMN was less effective as compared to 
nadolol. ISMN was well tolerated but failed to prevent bleeding 
[36]. These studies emphasize the superiority of beta-blockers 
as compared to ISMN.
B E T A - B L O C K E R S  A N D  I S O S O R B I D E  
M O N O N I T R A T E  ( I S M N )  V E R S U S  B E T A -
B L O C K E R S  M O N O T H E R A P Y
The addition of ISMN on beta-blockers achieves greater 
reduction of portal pressure. In 1996, Merkel et al showed that 
the addition of mononitrate isosorbide to beta-blockers was 
more effective than monotherapy. After a mean follow-up of 
30 months, the bleeding rate of patients who received nado-
lol was 18% as compared to 7.5% in the combination group 
[37]. Extended follow-up of these patients for more than 7 
years confirmed the superiority of combination therapy over 
monotherapy with nadolol [38].
Nevertheless, other studies did not confirm these results. 
A study by the Spanish Variceal Haemorrhage study group 
enrolled 349 cirrhotic patients who were randomized to receive 
either propranolol and placebo (174 patients) or propranolol 
and isosorbide mononitrate (175 patients). This study showed 
that propranolol is very effective in the primary prevention 
of variceal haemorrhage, while the low residual risk was not 
further decreased when ISMN was added. Treatment side 
effects were significantly more frequent in the group that 
received combination therapy, because of the higher occur-
rence of headache [39].
In another study, 57 cirrhotics with large esophageal vari-
ces and red colour sings were randomized to receive either 
ISMN plus nadolol (30 patients), or nadolol plus placebo (27 
patients). The study was interrupted due to increased mortality 
in a parallel study investigating the prevention of rebleeding 
in patients who received nadolol-containing and ISMN-con-
taining treatment; consequently, it was not possible to draw 
valid conclusions [40].
It, therefore, appears that data are not sufficient to support 
the combination therapy with beta-blockers plus ISMN in the 
primary prevention of variceal bleeding since it is not clearly 
superior to monotherapy with beta-blockers.
B E T A - B L O C K E R S  V E R S U S  S C L E R O T H E R A P Y
Sclerotherapy has been compared to the administration 
of beta-blockers in primary prevention setting. In one study 
by Adreani et al in 1990, 126 patients were randomised in 
3 groups: 43 patients received propranolol, 42 underwent 
sclerotherapy and 41 patients received placebo. After a two-
years follow-up, 2 patients passed away in the propranolol 
group, 9 in the sclerotherapy group and 13 in the control 
group. 24 patients bled (2 in the propranolol group, 9 in the 
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sclerotherapy group and 13 in the placebo group). The risk 
of first variceal bleeding was significantly lower in patients 
receiving propranolol as compared to placebo (p<0.004) or 
endoscopic sclerotherapy (p<0.03) while no difference was 
found between sclerotherapy and placebo, confirming the 
superiority of propranolol [3].
B E T A - B L O C K E R S  V E R S U S  S C L E R O T H E R A P Y  
A N D  B E T A - B L O C K E R S
In the PROVA study (1991), among 286 patients enrolled 
in the study 73 patients underwent sclerotherapy, 68 patients 
received propranolol, 73 patients underwent both treatments 
and 72 patients received no treatment. Effects on bleeding 
were similar in all groups, but mortality was increased in the 
group that received combination treatment [3].
A recent study by Avgerinos, et al. assessed prospectively 
the effectiveness of combination treatment (sclerotherapy and 
propranolol) as compared to propranolol alone in cirrhotic 
patients with varices and high (>18 mmHg) intraesophageal 
variceal pressure. Forty-two patients received propranolol 
and 44 patients combination therapy. Median follow-up was 
26.8±7.7 months and 24.6±9.8 respectively. 23% of patients 
who received combination treatment had at least one varices-
related or portal gastropathy-related bleeding episode versus 
14% in the group that received propranolol. Mortality was 
similar in both groups. Albumin was the only prognostic 
factor independently associated with survival. The authors 
concluded that endoscopic sclerotherapy should not be used 
for the primary prevention of variceal bleeding in cirrhotic 
patients [41].
So, it is well documented in the literature that sclerother-
apy as a single agent or in combination with a beta-blocker 
should not be used in this setting.
B E T A - B L O C K E R S  V E R S U S  L I G A T I O N  
Seven randomized studies [42-48] compared endoscopic 
treatment of high risk varices with beta-blockers.
In the De et al. study, 30 patients with 3 – 4 degree esoph-
ageal varices and HVPG ≥12 mmHG were randomized to 
receive propranolol (15 patients) or to undergo endoscopic 
ligation (15 patients). During follow-up (17.6±4.7 months), 
varices relapsed in 3 patients followed by bleeding in two 
of them. In the propranolol group, one patient bled from 
varices [42].
In a recent study, 172 patients with liver cirrhosis and II and 
III degree esophageal varices enrolled during a 6-year-period. 
44 patients underwent ligation, 66 patients received proprano-
lol and 62 patients received ISMN. Variceal haemorrhage was 
observed in 7% of patients. Bleeding risk was 6.2% (95% CI, 
0.0%-15.0%) in the ligation group, 19.4% (95% CI, 0.1%-
32.4%) in the group receiving propranolol, and 27.7% (95% 
CI, 14.2%-41.2%) in the group receiving ISMN. A substantial 
number of patients experienced side effects during treatment 
(45% in the propranolol group, 42% in the ISMN group, and 
2% in the ligation group), necessitating discontinuation of 
treatment in 30% of patients who received propranolol and 
21% of patients who received ISMN. There was no difference 
in mortality among the 3 groups. After a two year follow-up, 
there was a significant difference in bleeding risk between 
ligation and ISMN, favoring ligation, but not between ligation 
and propranolol [45]. The study has been criticised because 
only 9.1% of patients in band ligation group (4 patients) had 
large varices as compared to 18.2% of patients who received 
propranolol and 19.4% of patients who received ISMN, and 
this may be correlated with the favourable results of ligation. 
Lastly, 8% of patients had reduction of the heart rate without 
change of blood pressure, while it is well accepted that beta-
blockers maximum effectiveness is achieved when heart rate 
and pressure drop by 25% [49].
Sarin et al. enrolled 89 patients in a prospective study, 44 of 
them received propranolol and 45 had band ligation. Median 
follow-up was 14±9, and 13±10 months, respectively. After 18 
months, 12 patients in the propranolol group and 4 patients 
in the group that had band ligation bled. 3 out of 4 patients in 
the ligation group developed bleeding before the eradiation 
of varices while varices relapsed in 9 patients. 5 patients from 
each group died. Variceal haemorrhage was the cause of death 
for 4 patients in the propranolol group, and 3 patients in the 
band ligation group. There were no severe complications in the 
group of band ligation. In the propranolol group, treatment 
was discontinued in 2 patients because of side effects. The 
authors concluded that in patients with esophageal varices 
with high bleeding risk, endoscopic band ligation is safe and 
more effective than propranolol for the prevention of first 
bleeding [46]. However, serious concerns have been raised 
regarding the methodology of this trial and authors suggest 
that the available data are insufficient to support any change 
in our current practice [50].
In a meta-analysis, Imperiale et al. reported that endo-
scopic ligation decreased overall bleeding risk, but did not 
affect mortality; this led to the conclusion that it should be 
used only in patients with large esophageal varices who cannot 
tolerate beta-blockers. Five studies which compared ligation 
to no-treatment were analysed; two reported a statistically 
significant reduction of bleeding risk and bleeding-related 
mortality and one reported reduction of overall mortality. 
Four studies compared ligation to propranolol administration; 
only one favored ligation over propranolol in the reduction of 
risk for bleeding while none reported differences in mortality, 
either bleeding – related mortality or overall mortality [51]. 
Aoki et al. reported that ligation is an effective prophylactic 
treatment in many cases, but almost one quarter of patients 
can benefit more from receiving beta-blockers [52].
Recently, in a randomized multicenter study, 152 patients 
were randomized to receive either endoscopic treatment with 
ligation (75 patients) or pharmacological therapy with pro-
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pranolol (77 patients). No differences were observed in terms 
of variceal bleeding or mortality [47].
The theoretical advantage of endoscopic ligation over 
beta-blockers is the absence of contraindications, except for 
the endoscopy, less problems with compliance and treatment 
efficacy in all patients. Nevertheless, a widespread program of 
prophylactic ligation would be very costly and it does require 
repeated endoscopies to treat and monitor reappearance of 
varices.
Two more trials have been published recently in this area 
[43,48). One [48] did not find any differences between band-
ing and propranolol in the risk of first bleeding or mortality. 
The authors of the other study [43] suggested that proprano-
lol-treated cirrhotics with high-risk oesophageal varices had 
a significantly higher rate of bleeding from oesophageal 
varices and greater cumulative mortality than those who had 
banding. It should be noted that in this study the selection 
criteria excluded patients are most at risk of first bleeding, 
(severe coagulopathy unresponsive to blood product transfu-
sions, severe thrombocytopenia, gastric varices, documented 
hepatoma, portal or hepatic thrombosis and large-volume or 
tense ascites) i.e. the ones that clinicians may wish to treat 
intensively. 
The conflicting results of the studies, the small number of 
patients enrolled, as well as EVL cost lead to the conclusion 
that beta-blockers remain, in our opinion, the first line treat-
ment in the primary prevention of variceal haemorrhage.
L I G A T I O N  V E R S U S  S C L E R O T H E R A P Y
The studies investigating the effectiveness of treatment 
with esophageal varices ligation versus sclerotherapy have 
reported conflicting results [53-55]. Gameel et al. supported 
ligation as the most effective method [53], Gotoh et al. fa-
vored sclerotherapy [54] and Svodoba et al. found that both 
treatments are equally effective [55]. These studies present 
significant heterogeneity and thus, the data cannot be evalu-
ated meta-analytically. It should be noted that the likelihood 
of local complications following sclerotherapy is much higher 
and given the problems from the application of prophylactic 
sclerotherapy and the superiority of ligation versus sclero-
therapy, these studies lack scientific and ethical basis, but 
they are quoted here for historical reasons.
L I G A T I O N  +  B E T A - B L O C K E R S  V E R S U S  
L I G A T I O N  
In a recent study [56] 144 consecutive patients with high-
risk varices were randomly allocated to EVL plus propranolol 
(Group I, n = 72) or EVL alone (Group II, n = 72). EVL 
was done at 2-wk interval until obliteration of varices. Eleven 
patients bled, 5 in Group I and 6 in Group II. All patients bled 
before the obliteration of varices and the actuarial probability 
of first bleeding after 20 months was 7% in Group I and 11% 
in Group II (p= 0.72). Six patients died in the combination 
and 8 in EVL group. The authors concluded that both, EVL 
plus propranolol and EVL alone are effective in the primary 
prophylaxis of bleeding from high-risk varices. The addition of 
propranolol does not decrease the probability of first bleeding 
or death in patients on EVL. However, the probability of recur-
rence of varices is lower if propranolol is added to EVL.
A N G I O T E N S I N  I I  R E C E P T O R  
A N T A G O N I S T S
The antagonists of angiotensin II receptors decrease in-
trahepatic resistance but concerns have been raised for their 
administration in cirrhotic patients, because of their effects 
in systemic and renal circulation [57].
Losartan has been reported to be as effective as proprano-
lol in reducing portal pressure in cirrhotics who do not take 
diuretics. It appears to be superior in the prevention of bleed-
ing in cirrhotic patients without ascites, and in alcoholics [58]. 
Nevertheless, the results of two recent clinical studies [59,60] 
are not encouraging. Gonzales–Abraldes et al, investigated the 
hemodynamic and renal implications of losartan (25 patients) 
versus propranolol (15 patients) administered for 6 weeks in 
cirrhotic patients [59]. Losartan in a maximum dose of 50 
mg/day decreased HVPG but also decreased mean arterial 
pressure and GFR in Child-Pugh B patients. Similar results 
were reported in the other randomized study where irbesartan 
was administered [60]. It appears that angiotensin II recep-
tor antagonists should not be considered as an alternative 
treatment in patients with contraindications or intolerance 
to beta-blockers.
C O N C L U S I O N S
Endoscopic examination for the presence of esophageal 
varices and evaluation of their size should be performed in 
every patient diagnosed with liver cirrhosis. Surgery prevents 
bleeding, but the increased mortality and the increased risk 
of chronic encephalopathy makes this approach unacceptable. 
Prophylactic sclerotherapy should not be used, as it is relatively 
ineffective, inaccurate, and potentially risky. The treatment 
of choice is the administration of beta-blockers for life. It is 
an effective, cheap, easy to administer therapy, while it also 
prevents bleeding from portal gastropathy.
Primary prevention with band ligation appears to be safe 
and probably constitutes an alternative for a) patients with 
contraindications to beta-blockers, and b) patients that cannot 
tolerate the drug or do not have hemodynamic response to 
the drug administration. Nevertheless, it is an expensive treat-
ment requiring specialized staff and it cannot prevent gastric 
mucosal bleeding. So far, data are insufficient to support the 
combination of beta-blocker plus ISMN or the combination 
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of endoscopic plus pharmacological therapy.
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